Business
Q4 2025 Trading Update
Shield Therapeutics plc reported positive operating cash flow in Q4 2025 and full-year 2025 total revenues of approximately $50 million, a significant increase from $32 million in the prior year. The company's key product, ACCRUFeR®, saw its revenues grow by 56% to approximately $46 million in 2025, driven by a 21% rise in average net selling price to $223 and a 33% increase in total prescriptions to around 199,000. ACCRUFeR® net revenues in Q4 2025 reached $13.5 million, with prescriptions at approximately 61,000. The company ended 2025 with $11.6 million in cash and cash equivalents and anticipates delivering an operating profit in 2026. Disclaimer*
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\n \nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\n \nQ4 2025 Trading Update\n \nGenerated positive Cash flow in Q4 2025 with Total Group Revenues of c. $50m for full year 2025\nACCRUFeR® revenues grew 56% to c. $46m in 2025 with 21% increase in average net selling price to $223\nand 33% growth in total prescriptions to c.199,000\nCompany expects to deliver an operating profit in 2026\n \nLondon, UK, 21 January 2026: Shield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, announces that, in line with the Company's guidance, Shield has achieved positive operating cash flow in Q4 2025 and provides an unaudited full year trading update for the year ended 31 December 2025 (\"FY25\"). This period reflects the transition of the Company to a sustainable enterprise driven by continued ACCRUFeR® growth in the US and effective cost and working capital management. The Company also announces that it expects to deliver an operating profit in 2026.\n \nThe Company reported total revenues of c. $50m for FY25 ($32m revenues and other income in FY24) with ACCRUFeR® revenues growing 56% in the US and contributing $46m ($29m in FY24) through 21% growth in average net selling price to $223 and 33% growth in total prescriptions to c.199,000.\n \nQ4 2025 Key Business Metrics:\n· ACCRUFeR® net revenues of $13.5m ($11.2m Q4 2024).\n· ACCRUFeR® prescriptions of c. 61,000 (c. 41,000 in Q4 2024) representing the highest dispenses in any quarter since launch. Consignment-based prescriptions decreased c. 21% (c. 22% in Q4 2024) that were dispensed at a subsidised price to patients and were not yet reimbursed by payors.\n· ACCRUFeR® average net selling price of $222 ($237 in Q4 2024) impacted by an increase in covered rebated prescriptions compared t...